Evidence map›Paper›PMID 42694695›Full record

ArticleEndocrine oncology (Bristol, England)2026

Hematological neoplasms after PRRT: experience from long term follow-up of 173 patients in a tertiary center.

Joao Pedro Thimotheo Batista, Michael De La Iglesia, Hyun Kim, Vikas Prasad, Ravindra Shubha, Rama Suresh, Shuang Wu, Jingxia Liu, Meagan Jacoby, Samuel Urrutia and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine oncology (Bristol, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Joao Pedro Thimotheo BatistaMetroWest Medical Center and Framingham Union Hospital, Framingham, USA.
Michael De La IglesiaDepartment of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
Hyun KimDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
Vikas PrasadDepartment of Nuclear Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Ravindra ShubhaDepartment of Nuclear Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Rama SureshDepartment of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
Shuang WuDepartment of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
Jingxia LiuDepartment of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
Meagan JacobyDepartment of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
Samuel UrrutiaDepartment of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
Nikolaos A TrikalinosDepartment of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0001-8611-2182

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE ( Methods: We accessed the treatment files of patients with neuroendocrine neoplasms treated at our institution between January 2017 and January 2025 for pathology reports of myelodysplasia, leukemia, aplastic anemia and similar hematological disorders. Results: A total of 173 patients received Conclusions: The prevalence of tMN was 5.8% in our patient population. We have noted a higher than previously reported percentage of myelodysplasia post-PRRT, especially with additional treatments and longer follow-ups.

Indexed as

AMLlutetium DOTATATEMDSneuroendocrine neoplasmsPRRT

Identifiers

PMID42694695
PMCPMC13539410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.